XML 40 R26.htm IDEA: XBRL DOCUMENT
v3.24.2

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting [Abstract] |
Segment Information | 18. Segment Information The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the third quarter of 2020, Legacy Celularity managed operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. This change was prompted by certain organizational and personnel changes. The chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation among these segments. The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were approximately $143,889 and $401,066 as of December 31, 2023 and 2022, respectively. Financial information by segment is as follows:
|  | Year Ended December 31, 2023 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | — |  |  | $ | 5,441 |  |  | $ | 17,330 |  |  | $ | — |  |  | $ | 22,771 |
Gross profit |  |  | — |  |  |  | 3,791 |  |  |  | 2,964 |  |  |  | — |  |  |  | 6,755 |
Direct expenses |  |  | 28,694 |  |  |  | 1,752 |  |  |  | 9,720 |  |  |  | 40,876 |  |  |  | 81,041 |
Segment contribution |  |  | (28,694 | ) |  |  | 2,039 |  |  |  | (6,756 | ) |  |  | (40,876 | ) |  |  | (74,286 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 118,001 |  | (a) |  | 118,001 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (192,287 | )
(a) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  | (104,339 | ) |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  | 112,347 |  |  |  |
IPR&D impairment |  |  |  |  |  |  |  |  |  |  |  | 107,800 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 2,193 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 118,001 |  |  |  |
|  | Year Ended December 31, 2022 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | — |  |  | $ | 5,512 |  |  | $ | 12,463 |  |  | $ | — |  |  | $ | 17,975 |
Gross profit |  |  | — |  |  |  | 1,976 |  |  |  | (3,666 | ) |  |  | — |  |  |  | (1,690 | )
Direct expenses |  |  | 75,379 |  |  |  | 1,699 |  |  |  | 10,859 |  |  |  | 56,261 |  |  |  | 144,198 |
Segment contribution |  |  | (75,379 | ) |  |  | 277 |  |  |  | (14,525 | ) |  |  | (56,261 | ) |  |  | (145,888 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | (120,288 | ) | (b) |  | (120,288 | )
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (25,600 | )
(b) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  | (126,277 | ) |  |  |
Change in fair value of contingent stock consideration |  |  |  |  |  |  |  |  |  |  |  | 186 |  |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  | 3,610 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 2,193 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | (120,288 | ) |  |  |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration